{
    "Trade/Device Name(s)": [
        "BD PhoenixTM Automated Microbiology System - Cefepime (0.5-64 \u03bcg/mL) and Ceftriaxone (0.5-64 \u03bcg/mL)",
        "BD Phoenix\u2122M Automated Microbiology System for use with Cefepime (0.5-64 \u00b5g/mL) and Ceftriaxone (0.5-64 \u03bcg/mL)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K060444/s1",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K032675",
        "K032655"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "April 12, 2006",
    "Summary Letter Received Date": "February 21, 2006",
    "Submission Date": "February 20, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefepime",
        "Ceftriaxone"
    ],
    "Specimen Type(s)": [
        "Isolates from pure culture of Gram-negative aerobic and facultative anaerobic bacteria",
        "Isolates from pure culture of Gram-positive bacteria"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix Automated Microbiology System",
        "BD Phoenix instrument and software"
    ],
    "Method(s)/Technology(ies)": [
        "Broth microdilution",
        "Automated antimicrobial susceptibility testing",
        "Redox indicator detection"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "In vitro quantitative MIC determination"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "Panel",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System panels with Cefepime and Ceftriaxone for antimicrobial susceptibility testing of aerobic and facultative anaerobic bacteria.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative and Gram-positive bacteria from pure culture, including additional organism groups, using Cefepime and Ceftriaxone on BD Phoenix panels.",
    "fda_folder": "Microbiology"
}